Plasma metabolomic signatures of breast cancer

Abstract

BackgroundBreast cancer is a common malignant tumor. A large number of medical evidence shows that breast cancer screening can improve the early diagnosis rate and reduce the mortality rate of breast cancer. In the present study, a wide range of targeted metabolomics profiling was conducted to investigate the plasma signatures of breast cancer.MethodsA total of 86 patients with benign breast abnormalities (L group) and 143 patients with breast cancer (E group) were recruited. We collected their plasma samples and clinical information. Metabolomic analysis, based on the coverage of a wide range of targeted metabolomics was conducted with ultraperformance liquid chromatography- triple quadrupole-linear ion trap mass spectrometer (UPLC-QTRAP-MS).ResultsWe identified 716 metabolites through widely-targeted metabolomics. Serotonergic synapse was the main different metabolic pathway. The fold change of 14 metabolites was considered significantly different (fold change <0.67 or fold change >2; p < 0.05). By combining all the 14 metabolites, we achieved differentiation of L group vs. E group (AUC = 0.792, 95%Cl: 0.662–0.809).ConclusionThis study provided new insights into plasma biomarkers for differential diagnosis of benign abnormalities and breast cancer.

Metabolomics-transcriptomics joint analysis: unveiling the dysregulated cell death network and developing a diagnostic model for high-grade neuroblastoma

“…Furthermore, Xu et al conducted targeted metabolomics analysis on a cohort of 86 patients with benign breast lesions and 143 patients diagnosed with breast cancer, aiming to investigate the plasma characteristics associated with breast cancer. A total of 716 metabolites were identified, revealing serotonergic synapses as the predominant differential metabolic pathway (9). Transcriptomics employs highthroughput sequencing techniques to investigate the complete set of transcribed mRNAs within specific cells, tissues, or individuals at a given time and state.…”